Scholarlink

Purpose <p>Busulfan is an important myeloablative agent in various conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) in pediatric patients. This retrospective study compares three different routes of busulfan administration and their impact on transplantation-related mortality (TRM) and overall survival (OS).</p> Methods <p>The study included 250 pediatric patients with malignant and non-malignant diseases who underwent HSCT at the Department of Pediatrics, Jena University Hospital, Jena, Germany. One hundred forty-eight patients received busulfan orally without therapeutic drug monitoring (TDM) (group 1), 62 patients received busulfan intravenously (i.v.) without TDM (group 2) and 40 patients received busulfan i.v. with additional TDM (group 3).</p> Results <p>The TRM rate at 5&#xa0;years after transplantation for all patients was 40.5% for group 1, 25.2% for group 2, and 8.4% for group 3 (<i>p</i> &lt; 0.001). The TRM rate at 5&#xa0;years after transplantation for patients with malignant diseases only was 40.3% for group 1 compared&#xa0;to 28.4% for group 2 and 15.3% for group 3 (<i>p</i> = 0.051). For patients with non-malignant diseases, group 1 showed a TRM rate of 43.8% compared to 15.4% in group 2 and 4.6% in group 3 (<i>p</i> = 0.009). In addition, the 5-year OS rate for all patients was 39.9% for group 1, 61.2% for group 2, and 83.9% for group 3 (<i>p</i> &lt; 0.001). Regarding the OS of the groups for patients with only malignant or only non-malignant diseases, we obtained similar results with <i>p</i>-values of <i>p</i> = 0.017 and <i>p</i> = 0.007, respectively. The cumulative incidence of hepatic sinusoidal obstruction syndrome (SOS) for patients with malignant diseases and a cumulative AUC &gt; 85.0&#xa0;mg/L x h was 55.6%, while patients with malignant diseases and a cumulative AUC &lt; 85.0&#xa0;mg/L x h showed a cumulative incidence of 11.1% (<i>p</i> = 0.038).</p> Conclusion <p>In this study, we demonstrate that patients with i.v. administration of busulfan with TDM had a significantly lower rate of TRM and a significantly improved OS compared to patients who received i.v. administration of busulfan without TDM, who, in turn, had a better outcome than patients with oral busulfan administration. Additionally, these data emphasize the clinical relevance of AUC measurements in patients with malignant diseases to prevent hepatic SOS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月4日

查看全文
  • Stephanie Hämmerle,
  • Jana Ernst,
  • Regula Steiner,
  • Tayfun Güngör,
  • Till Milde,
  • Bernd Gruhn

摘要

Purpose

Busulfan is an important myeloablative agent in various conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) in pediatric patients. This retrospective study compares three different routes of busulfan administration and their impact on transplantation-related mortality (TRM) and overall survival (OS).

Methods

The study included 250 pediatric patients with malignant and non-malignant diseases who underwent HSCT at the Department of Pediatrics, Jena University Hospital, Jena, Germany. One hundred forty-eight patients received busulfan orally without therapeutic drug monitoring (TDM) (group 1), 62 patients received busulfan intravenously (i.v.) without TDM (group 2) and 40 patients received busulfan i.v. with additional TDM (group 3).

Results

The TRM rate at 5 years after transplantation for all patients was 40.5% for group 1, 25.2% for group 2, and 8.4% for group 3 (p < 0.001). The TRM rate at 5 years after transplantation for patients with malignant diseases only was 40.3% for group 1 compared to 28.4% for group 2 and 15.3% for group 3 (p = 0.051). For patients with non-malignant diseases, group 1 showed a TRM rate of 43.8% compared to 15.4% in group 2 and 4.6% in group 3 (p = 0.009). In addition, the 5-year OS rate for all patients was 39.9% for group 1, 61.2% for group 2, and 83.9% for group 3 (p < 0.001). Regarding the OS of the groups for patients with only malignant or only non-malignant diseases, we obtained similar results with p-values of p = 0.017 and p = 0.007, respectively. The cumulative incidence of hepatic sinusoidal obstruction syndrome (SOS) for patients with malignant diseases and a cumulative AUC > 85.0 mg/L x h was 55.6%, while patients with malignant diseases and a cumulative AUC < 85.0 mg/L x h showed a cumulative incidence of 11.1% (p = 0.038).

Conclusion

In this study, we demonstrate that patients with i.v. administration of busulfan with TDM had a significantly lower rate of TRM and a significantly improved OS compared to patients who received i.v. administration of busulfan without TDM, who, in turn, had a better outcome than patients with oral busulfan administration. Additionally, these data emphasize the clinical relevance of AUC measurements in patients with malignant diseases to prevent hepatic SOS.